About

About Mediwhale Co Ltd. Mediwhale leverages retinal imaging and AI to advance early detection, personalized risk assessment, and preventive care. Retinal AI enables the early identification of cardiometabolic risk, supporting proactive and preventive healthcare. Mediwhale offers the world’s first regulatory-approved AI solution for cardiovascular risk assessment using retinal imaging. Mediwhale is a company specializing in retinal AI biomarkers for predicting cardiovascular, renal, and metabolic risks. Our innovative technology enables a 30-second eye scan to accurately identify future risks of cardiovascular disease, chronic kidney disease, and existing ocular conditions, providing physicians and patients with actionable insights for preventive care. Mediwhale’s solutions are called “Dr. Noon” are already being utilized in clinical settings across South Korea, the EU, UK, Dubai, and other Asia regions, supported by regulatory approvals and a reimbursement code. Our technology is backed by robust clinical evidence, with key studies published in leading journals such as The Lancet Digital Health and European Heart Journal Digital Health.